There is mixed trial evidence concerning the use of low molecular weight heparin (LMWH) in patients with acute ischaemic stroke.
Some trials suggest a reduction in mortality/dependency at six months in those treated with LMWH.
However recent evidence suggests that LMWH has no significant benefit over aspirin for acute ischaemic stroke in patients with atrial fibrillation.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page